Clinical study of intratumoral dendritic cells(DC) injection after radiofrequency ablation(RFA) therapy for the treatment of hepatitis C virus-related hepatocellular carcinoma(HCC) patients

Clinical study of intratumoral dendritic cells(DC) injection after radiofrequency ablation(RFA) therapy for the treatment of hepatitis C virus-related hepatocellular carcinoma(HCC) patients - Intratumoral DC injection after RFA for the treatment of HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000971

Enrollment

Registered

2008-01-07

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Intratumoral dendritic cells injection Radiofrequency ablation therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV-related HCC patients who are not completely controlled by hepatic resection, local treatment, embolization therapy, hepatic intra-arterial chemotherapy and so on, and who meet the followings : - RFA is applicable; - Performance status is 0-1; - No serious abnormality in bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Interstitial pneumonia, pulmonary fibrosis, or drug-induced pneumonia , or predisposition to them; - Continuous systemic administration of steroids; - Active autoimmune diseases or predisposition to them; - Other cancers; - Uncontrolled infection

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological responses, Clinical responses	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026